CHKB-CPT1B

Across TCGA pan-cancer cohorts, CHKB-CPT1B RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated CHKB-CPT1B data layer.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher CHKB-CPT1B RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated CHKB-CPT1B expression acts as an unfavorable survival marker, although some lineages such as BLCA and SKCM show a favorable association.

BLCA, MESO, and KIRC are the cancer types where CHKB-CPT1B RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	II,III,IV	0.414	0.246	<.001	128	view →
MESO	DFS	Tertile	All	0.265	0.480	.001	108	view →
KIRC	DFS	Tertile	All	0.526	0.720	<.001	86	view →
SKCM	DFS	Quartile	All	0.790	0.636	.001	48	view →
THCA	OS	Median	II,III,IV	0.905	1.000	<.001	29	view →
COAD	DFS	Quartile	III,IV	0.559	0.886	.004	25	view →
PRAD	DFS	Median	All	0.847	0.920	.007	24	view →
ACC	OS	Quartile	All	0.647	0.927	.008	22	view →
CESC	DFS	Quartile	III,IV	0.569	0.898	.014	18	view →
UCS	DFS	Quartile	II,III,IV	0.489	0.170	.019	18	view →
HNSC	DFS	Quartile	All	0.773	0.664	.032	16	view →
STAD	OS	Tertile	IV	0.744	0.256	.010	13	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

CHKB-CPT1B–BLCA (DFS)

Open the BLCA breakdown →